Back

Metabolic disorders predict future impairment of kidney function in the Japanese general population

28 August 2023 (10:35 - 10:45)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Fumihiko Kin

Enshu Hospital, Hamamatsu (Japan)

5 More presentations in this session

Presentation thumbnail
ZNF259 rs964184 genetic variant is associated with metabolic syndrome in a Portuguese population
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Effect of exercise in incident atrial fibrillation among diabetes mellitus with different diabetes duration
Miss J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Outcomes of diabetic patients with acute coronary syndromes treated with aspirin in primary prevention
Doctor H. Costa (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Myocardial performance index improves prediction of major adverse cardiovascular events and heart failure in type 1 and type 2 diabetes without known heart disease: Thousand&1 and Thousand&2 study
Doctor H. Bahrami (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
Doctor O. Kobo (Hadera, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart
Video

The Event

Event poster

ESC Congress 2023

28 August 2023 10:35 CET
You may be interested in
thumbnail
Congress Session
Metabolic drivers of cardiovascular disease
thumbnail
Congress Presentation
Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease: results from a UK electronic health record database
thumbnail
Congress Presentation
Cardiovascular-kidney-liver-metabolic-health:a population-based study on the prognostic impact of the coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources